
|Articles|February 15, 2004
New drug application sought for combination IOP medication
Alcon is asking the FDA to approve a new drug application for its travoprost 0.004% plus timolol 0.5% fixed combination (TTFC) for the reduction of IOP in the treatment of glaucoma.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
2
Glaucoma innovation: Eight themes to watch in 2026
3
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
4
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
5












































